|
Editor's Note:
In October 2009, we attended the BIO Investor Forum, a meeting which revealed some new biotech companies to watch in 2010. In January, we attended the JP Morgan Healthcare Conference for 2010. We noticed that there were just as many attendees as in past years. Some of the most well attended sessions involved the luncheons that featured Jamie Dimon, and Tom Daschle talk about pending healthcare reform. We were also very impressed by the overflow attendance in a smallish room upstairs this featured a panel about molecular diagnostics and areas of personalized medicine. In February, we attended the 2010 CHI Molecular Medicine Tri-Conference. Wow, that meeting grew to eleven tracks. Much of the content focused on different aspects of enabling personalized medicine opportunities. Other tracks focused on cancer research, biologics, stem cells, RNAi and information technology in bio/ pharma research. We also visited the MacWorld Conference to see what's new in Apple computing. We enjoyed the lively discussions that these meetings produced. These events provided clear signs of emerging opportunity as we navigate the brave world of a down economy. Then on March 23rd, President Obama signed the new healthcare reform bill into law. What does it really mean for the industry?
- Jay Myers, Editor and Publisher
|
|
